These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2006-006179-19 ESTUDIO INTERNACIONAL DE FASE II PARA EVALUAR UNA ASOCIACIÓN CHOP-RITUXIMAB CON CONSOLIDACIÓN PRECOZ CON IBRITUMOMAB-TIUXETAN-Y90 EN PACIENTES DE EDADES ENTRE 65 Y 80 AÑOS AFECTADOS DE UN LINFOMA MALI... not-yet-due
Ongoing 2007-000818-36 Etude de phase III randomisée comparant deux modes d’administration des facteurs de croissance (G-CSF) non pégylés dans la prévention secondaire des neutropénies sévères not-yet-due
Ongoing, reported early 2007-004384-22 ETUDE DE PHASE II EVALUANT UNE RADIOTHERAPIE - CHIMIOTHERAPIE + CETUXIMAB CHEZ DES PATIENTS PORTEURS D’UN CARCINOME EPIDERMOÏDE DE LA CAVITE BUCCALE, DE L’OROPHARYNX, DE L’HYPOPHARYNX OU DU LARYNX HIS... not-yet-due
Ongoing, reported early 2008-004136-20 ETUDE PILOTE DE DEPISTAGE DES SUJETS DEFICITAIRES EN DIHYDROPYRIMIDINE DESHYDROGENASE. APPLICATION AU CANCER DU SEIN TRAITE PAR FLUOROPYRIMIDINE ORALE. not-yet-due
Ongoing 2008-004137-21 EFFETS DU SUNITINIB DANS L'EXPRESSION DU VEGF ET DE L'INTERLEUKINE 8 : EXPLICATION DES EFFETS ANTI ANGIOGENIQUES not-yet-due
Ongoing 2009-015120-28 Etude d’un traitement préopératoire par Cisplatine-Docétaxel et radiothérapie dans le cancer bronchique non à petites cellules de stade IIIA/IIIB (T1-4, N2): Etude de phase II not-yet-due
Ongoing 2012-005036-28 Pharmacogenetic study in castration-resistant prostate cancer patients treated with abiraterone acetate not-yet-due
Exempt 2014-001578-32 A phase I/II study of pazopanib in combination with temozolomide in patients with newly diagnosed glioblastoma multiforme after surgery and RT-CT (PAZOGLIO study) not-yet-due
Ongoing 2017-002037-31 Study of the impact of DPD activity on the efficacy of capecitabine not-yet-due
Ongoing 2017-004239-35 Randomized Phase II, 2-arm Study of Immunomodulation with Atezolizumab concomitant with High Dose Radiation (SBRT) Versus SBRT Alone in Patients with Oligometastatic Sarcomas not-yet-due